US11360093B2 - Colorectal cancer diagnostic composition, and method for detecting diagnostic marker - Google Patents

Colorectal cancer diagnostic composition, and method for detecting diagnostic marker Download PDF

Info

Publication number
US11360093B2
US11360093B2 US16/111,087 US201816111087A US11360093B2 US 11360093 B2 US11360093 B2 US 11360093B2 US 201816111087 A US201816111087 A US 201816111087A US 11360093 B2 US11360093 B2 US 11360093B2
Authority
US
United States
Prior art keywords
protein
colon cancer
krs
aimp1
trna synthetase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/111,087
Other languages
English (en)
Other versions
US20190018015A1 (en
Inventor
Sunghoon Kim
Min Chul Park
Peter Charles Goughnour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinal Bioconvergence Research Center
Original Assignee
Medicinal Bioconvergence Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinal Bioconvergence Research Center filed Critical Medicinal Bioconvergence Research Center
Assigned to MEDICINAL BIOCONVERGENCE RESEARCH CENTER reassignment MEDICINAL BIOCONVERGENCE RESEARCH CENTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOUGHNOUR, Peter Charles, KIM, SUNGHOON, PARK, MIN CHUL
Publication of US20190018015A1 publication Critical patent/US20190018015A1/en
Application granted granted Critical
Publication of US11360093B2 publication Critical patent/US11360093B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)

Definitions

  • the present invention relates to a colorectal or colon cancer diagnostic composition, and a method for detecting a diagnostic marker of a colorectal or colon cancer. More specifically, the present invention relates to a composition for diagnosing a colon cancer comprising an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1), a method for detecting a marker of a colon cancer so as to provide information necessary for diagnosis of a colon cancer, and use of an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) for the preparation of a diagnostic agent for a colon cancer.
  • KRS lysyl-tRNA synthetas
  • cancer malignant neoplasm
  • the number of cancer (malignant neoplasm) deaths in the Republic of Korea was 62,887, which is 25.5% (29.6% of male deaths and 20.5% of female deaths) among a total of 246,515 deaths in the Republic of Korea (512 deaths per 100,000 population).
  • Cancer is the number one cause of death (130.7 deaths per 100,000 population).
  • Lung, stomach, liver, colon and pancreatic cancers predominate in order of mortality rate, while deaths from these top five cancers account for about 70% of all cancer deaths.
  • the major causes of cancer deaths in male are lung, stomach, liver and colon cancers, while the deaths from the four major cancers (28,147) account for 70% of all male cancer deaths (40,177).
  • the major causes of cancer deaths in female are gastric, lung, liver, colon and pancreatic cancers, while the deaths from these five cancers (13,630) account for 60% of all female cancer deaths (22,710).
  • Colon or colorectal cancer refers to malignant tumors of the colon and rectum, with a worldwide incidence rate of 945,000 new cases (9.4% of worldwide total cancer incidence) and mortality rate of 492,000 deaths (7.9% of total cancer deaths) in 2000 is the third highest in all cancers. When compared by gender, it occurs at a similar rate in male and female (male:female 1.1:1). Because its prognosis is relatively good compared to other cancers, the survival rate for people with colon cancer is the second highest in the world after breast cancer, while estimated 2.4 million people are still alive after being diagnosed with colon cancer within the past 5 years (Parkin D M, Global cancer statistics in the year 2000, Lancet Oncol 2:533-543, 2001). The 5-year survival rate for colon cancer prognosis is 90% or higher in early stage (stage I) patients, whereas being only 5% in metastatic (stage IV) patients (Cancer Facts and Figures 2004. American Cancer Society, 2004).
  • colon cancer has been increasing steadily for the past four years from 1999 to 2002, in 2002 compared to 1999, the crude incidence rate of cancer (the number of new cancer per 100,000 population) has increased by 36.4% from 22.5 to 30.7 in male, and by 22.9% from 18.8 to 23.1 in female, leading to its overall increase by 30.6% from 20.6 to 26.9 (Survival rate of cancer patients in 1993-2002 and Cancer Incidence in 1993-2002, Ministry of Health and Welfare, 2007. 7).
  • the fourth ranked (9.5%) cancer deaths there were 3,453 male deaths in fourth place (8.0%), and 2,824 female deaths in third place (11.5%).
  • colon cancer is the most common cancer with the highest mortality rate in the last decade after lung cancer (2006 statistics on death and its causes, Statistics Korea, 2007. 9).
  • colon cancer In the case of colon cancer, since its development is slow from a pre-cancerous lesion that can be removed or from an early-stage cancer that can be treated, screening for colon cancer has a potential to reduce its incidence and mortality rates. It is believed that screening for colon cancer in both male and female over the age of 50 can reduce colon cancer mortality (Walsh J M & Terdiman J P, JAMA 289:1288-96, 2003). However, compliance and supply rates for colonoscopy, the most reliable screening method currently available, are low. Oppositely, the fecal occult blood test (FOBT), the most widely used non-invasive screening option, has several important limitations, including its low sensitivity above all.
  • FOBT fecal occult blood test
  • the present inventors have completed the present invention after they have found a biomarker which can be detected simply and rapidly in the serum of colon cancer patients and has a high sensitivity and specificity, as a result of efforts to develop a biomarker capable of effectively diagnosing colon cancer.
  • an aspect of the present invention is to a composition for diagnosing a colon cancer comprising an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1).
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • kits for diagnosing a colon cancer comprising an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1).
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • Another aspect of the present invention is to provide a method for diagnosing and treating a colon cancer in a subject, the method comprising the steps of:
  • Another aspect of the present invention is to provide a method for screening an anti-colon cancer agent, the method comprising the steps of:
  • mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) in the sample under the presence or absence of the anti-colon cancer agent candidate;
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • Another aspect of the present invention is to provide use of an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) for the preparation of a diagnostic agent for a colon cancer.
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • An embodiment according to an aspect of the present invention provides a composition for diagnosing a colon cancer comprising an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1).
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • kits for diagnosing a colon cancer comprising an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1).
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • An embodiment according to another aspect of the present invention provides a method for diagnosing and treating a colon cancer in a subject, the method comprising the steps of:
  • An embodiment according to another aspect of the present invention provides a method for screening an anti-colon cancer agent, the method comprising the steps of:
  • mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) in the sample under the presence or absence of the anti-colon cancer agent candidate;
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • An embodiment according to another aspect of the present invention provides use of an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) for the preparation of a diagnostic agent for a colon cancer.
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • the present invention provides a composition for diagnosing a colon cancer comprising an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1).
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • the present inventors were the first to confirm that KRS and AIMP1 were significantly increased in colon cancer patients than normal controls, and that they are highly valuable as new colon cancer diagnostic markers.
  • each of the markers was found to have excellent sensitivity and specificity in diagnosing colon cancer.
  • the sensitivity and specificity of the diagnostic markers according to the present invention were significantly superior to these of CA19-9, one of the conventional colon cancer diagnostic markers.
  • the present invention provides a composition for diagnosing colon cancer comprising an agent for measuring the expression level of lysyl-tRNA synthetase (KRS) and/or aminoacyl-tRNA synthetase complex-interacting multifunctional Protein 1 (AIMP1), that is, the protein or mRNA level of KRS and/or AIMP1.
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional Protein 1
  • Aminoacyl-tRNA synthetase is an enzyme that attaches a specific amino acid to its corresponding tRNA.
  • it is composed of 23 enzymes including three enzymes involved in the formation of multisynthetase complexes such as AIMP1 (p43), (AIMP2) p38, and (AIMP3) p18.
  • AIMP1 p43
  • AIMP2 p38
  • AIMP3 p18
  • some enzymes also exist in a free form.
  • KRS and AIMP1 possess various other functions in a specific environment.
  • KRS was shown to induce an immune response through macrophage activation.
  • KRS which is extra cellularly secreted by TNF- ⁇ , has been reported to increase the activity of macrophage cells by TNF- ⁇ by signaling via p38 mitogen activated kinase and the like, or to promote cell migration.
  • KRS has also recently been shown to be involved in a variety of diseases. It has been reported that autologous antibodies to KRS are present in patients with inflammatory muscle diseases, while KRS is involved in binding to SOD1 enzyme in a patient with SOD1 gene mutation causing Lou Gehrig's disease.
  • KRS can be used as a diagnostic marker for colon cancer because its protein level in the serum of colon cancer patients is significantly higher than that of normal control subjects, while such findings are first disclosed in the present invention.
  • AIMP1 (ARS-interacting multi-functional protein 1) is a protein previously known as p43 protein and recently renamed as AIMP1 (Sang Gyu Park, et al., Trends in Biochemical Sciences, 30:569-574, 2005).
  • the AIMP1 is a protein consisting of 312 amino acids, which binds to a multi-tRNA synthetase complex (Deutscher, M. P., Method Enzymol, 29, 577-583, 1974; Dang C. V. et al., Int. J. Biochem. 14, 539-543, 1982; Mirande, M. et al., EMBO J. 1, 733-736, 1982; Yang D. C. et al., Curr. Top Cell. Regul.
  • AIMP1 is known to act on a variety of target cells such as monocytes/macrophages, endothelial cells and fibroblasts. However, it has not been known that AIMP1 can be used as a diagnostic marker for colon cancer because its protein level in the serum of colon cancer patients is significantly higher than that of normal control subjects, while such findings are first disclosed in the present invention.
  • diagnosis marker refers to a substance or an agent that can diagnose by distinguishing colon cancer patients from normal controls, including an organic biomolecule such as a polypeptide or a nucleic acid (e.g. mRNA or the like), a lipid, a glycolipid, a glycoprotein or a sugar (monosaccharide, disaccharide, oligosaccharide and the like), which shows an increase or decrease in the colon cancer patients as compared with the normal controls.
  • a polypeptide or a nucleic acid e.g. mRNA or the like
  • lipid e.g. a lipid, a glycolipid, a glycoprotein or a sugar (monosaccharide, disaccharide, oligosaccharide and the like)
  • the colon cancer diagnostic marker of the present invention is KRS (lysyl-tRNA synthetase) or AIMP1 (aminoacyl-tRNA synthetase complex-interacting multifunctional Protein 1) genes and proteins encoded thereby, which specifically show higher expression levels in cancer cells as compared with cells of normal tissue.
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional Protein 1
  • the term ‘expression’ means that a protein or a nucleic acid is produced in a cell.
  • protein is used interchangeably with ‘polypeptide’ or ‘peptide’ and for example, refers to a polymer of amino acid residues as commonly found in naturally occurring proteins.
  • polynucleotide or ‘nucleic acid’ refers to deoxyribonucleotide (DNA) or ribonucleotide (RNA) in the form of single strand or double strands. Unless otherwise limited, it also includes known analogs of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides.
  • mRNA is a RNA that transfers genetic information (gene-specific nucleotide sequence) to ribosomes that specify amino acid sequences from a specific gene during protein synthesis.
  • diagnosis means identifying the presence or characteristics of a pathological condition.
  • the diagnosis as used herein is to determine the expression level of the KRS and/or AIMP1 gene, that is, the protein or mRNA level of one or more of the markers is measured to ascertain the existence of pathological incidence or development of colon cancer.
  • the agent for measuring mRNA expression level may be a probe or a primer set that specifically binds to mRNA of KRS and/or AIMP1.
  • the KRS and AIMP1 mRNA may be derived form a mammal including a human, preferably the mRNA of KRS comprising the nucleotide sequence of SEQ ID NO: 1 and the mRNA of AIMP1 comprising the nucleotide sequence of SEQ ID NO: 2.
  • the diagnostic composition of the present invention comprising a probe or primer set specific for mRNA of at least one selected from the group consisting of KRS and AIMP1 as an agent for measuring the expression level of at least one selected from the group consisting of KRS and AIMP1, may further comprise an agent necessary for known methods of detecting RNAs.
  • the known methods of detecting RNAs using the composition according to the present intention may be used without limitation to determine the mRNA level of the markers in a subject.
  • the term ‘primer’ refers to a short single strand oligonucleotide that acts as a starting point for DNA synthesis.
  • the primer specifically binds to a polynucleotide as a template under suitable buffer and temperature conditions, and DNA is synthesized by the addition of nucleoside triphosphate having a base complementary to the template DNA by DNA polymerase.
  • the primer is generally composed of 15 to 30 nucleotide sequences, and a melting temperature (Tm) at which the primer binds to the template strand varies depending on the composition and length of bases.
  • the primer for measuring the mRNA level of the above markers in the present invention does not need to have a sequence completely complementary to its corresponding gene sequence, while it is sufficient that the primer has a sequence length and complementary appropriate for the purpose of measuring the mRNA level by amplifying a particular region of mRNA or cDNA through DNA synthesis.
  • the primer for such an amplification reaction is composed of a set (pair) of strands complementarily binding to a template (or sense) strand and an opposite (antisense) strand at the ends of a specific region of the mRNA to be amplified, respectively.
  • Primers can be easily designed by those skilled in the art with reference to the KRS or AIMP1 mRNA or cDNA sequence.
  • the primer of the present invention is preferably a set, a pair or combination thereof which specifically binds to the nucleotide sequence of KRS mRNA of SEQ ID NO: 1 or the nucleotide sequence of AIMP1 mRNA of SEQ ID NO: 2, most preferably at least one forward primer selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 6, and at least one reverse primer selected from the group consisting of SEQ ID NO: 7 and SEQ ID NO: 8, while being not limited thereto.
  • SEQ ID NO: 5 and SEQ ID NO: 7 are primers specific to the nucleotide sequence of KRS mRNA
  • SEQ ID NO: 6 and SEQ ID NO: 8 are primers specific the nucleotide sequence of AIMP1 mRNA.
  • probe refers to a fragment of a polynucleotide, such as RNA or DNA having a base pair length of several to several hundreds, which can specifically bind to mRNA or cDNA (complementary DNA) of a specific gene, while the probe is labeled so that the presence or expression level of mRNA or cDNA to be bound can be confirmed.
  • probes complementary to KRS or AIMP1 mRNA may be used for the diagnosis of colon cancer by measuring the mRNA level of KRS of AIMP1 through performing hybridization with a sample of a subject. The selection and hybridization conditions of the probes can be appropriately determined according to techniques known in the art.
  • the primer or probe of the present invention can be chemically synthesized using a phosphoramidite solid support synthesis method or other well-known methods.
  • the primer or probe may be modified in various ways according to methods known in the art, so long as it does not interfere with its hybridization with mRNA of KRS of AIMP1.
  • modifications include, but are not limited to, methylation, capping, substitution with one or more of the natural nucleotide analogs, and modifications between nucleotides such as the binding of labeling materials using uncharged linkers (e.g., methylphosphonate, phosphotriester, phosphoramidate, and carbamate) or charged linkers (e.g., phosphorothioate, and phosphorodithioate), and fluorescences or enzymes.
  • uncharged linkers e.g., methylphosphonate, phosphotriester, phosphoramidate, and carbamate
  • charged linkers e.g., phosphorothioate, and phosphorodithioate
  • the agent for measuring the protein level may be an antibody that specifically binds to KRS or AIMP1 protein, respectively.
  • the KRS and AIMP1 protein may be derived form a mammal including a human, preferably the KRS protein comprises the amino acid sequence of SEQ ID NO: 3 and the AIMP1 protein comprises the amino acid sequence of SEQ ID NO: 4, respectively.
  • the term ‘antibody’ means an immunoglobulin that specifically binds to an antigenic site.
  • the antibody according to the present invention does not react with other proteins including different types of ARS other than the KRS or AIMP1, and specifically binds only to the KRS or AIMP1 protein.
  • the KRS or AIMP1 antibody may be produced by cloning each gene into an expression vector to obtain a protein encoded by the gene, followed by its preparation from the obtained protein according to a conventional method in the art.
  • a fragment of KRS or AIMP1 protein comprising a KRS or AIMP1 antigenic site may be used to prepare antibodies specific to each of said proteins.
  • the form of the antibody of the present invention is not particularly limited and includes a polyclonal antibody and a monoclonal antibody.
  • the antibody according to the present invention includes a portion of whole antibody as long as it has an antigen-antibody binding property. Some of the whole antibodies are also included in the antibodies of the present invention, while including all kinds of immunoglobulin antibodies that specifically bind to the KRS or AIMP1. For example, it includes an antibody in complete form having two full-length light chains and two full-length heavy chains, as well as functional fragments of antibody molecules, that is, Fab, F(ab′), F(ab′)2 and Fv having an antigen binding function. Further, the antibody of the present invention includes a specific antibody such as a humanized antibody, a chimeric antibody, and a recombinant antibody as long as it can specifically bind to the KRS of AIMP1 protein.
  • the diagnostic composition of the present invention which comprises each of the marker protein-specific antibodies as an agent for measuring the expression level of KRS or AIMP1, may further comprise an agent necessary for a known method for detecting a protein.
  • the known method of detecting proteins using the present composition may be used without limitation to determine the level of one or more proteins selected from the group consisting of KRS and AIMP1 in a subject.
  • kits for diagnosing a colon cancer comprising an agent for measuring a mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1).
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • the diagnostic kit of the present invention may comprise one or more other compositions, solutions or devices suitable for assay, as well as antibodies selectively recognizing at least one protein selected from the group consisting of KRS and AIMP1 as a marker, primers and probes that recognize mRNA of at least one selected from the group consisting of KRS and AIMP1 as a marker.
  • the diagnostic kit may be a diagnostic kit comprising essential elements necessary for performing a reverse transcription polymerase chain reaction (RT-PCR).
  • a RT-PCR kit contains a pair of primers specific for each marker gene.
  • the primer is a nucleotide having a sequence specific to the nucleic acid sequence of each marker gene, with about 7 bp to 50 bp in length, more preferably about 10 bp to 30 bp in length. It may also contain a primer specific for the nucleic acid sequence of a control gene.
  • RT-PCR kits may comprise test tubes or other appropriate containers, reaction buffers (with varying pH and magnesium concentrations), deoxynucleotides (dNTPs), enzymes such as Taq polymerase and reverse transcriptase, DNAse, RNAse inhibitor DEPC-treated water, and sterile water.
  • reaction buffers with varying pH and magnesium concentrations
  • dNTPs deoxynucleotides
  • enzymes such as Taq polymerase and reverse transcriptase
  • DNAse DNAse
  • RNAse inhibitor DEPC-treated water sterile water.
  • the DNA chip kit may comprise a substrate on which a cDNA or oligonucleotide corresponding to a gene or a fragment thereof is attached, reagents, preparations, and enzymes for producing a fluorescent-labeled probe.
  • the substrate may also comprise a cDNA or oligonucleotide corresponding to a control gene or fragment thereof.
  • ELISA kits contain antibodies specific for a marker protein.
  • Antibodies as used include monoclonal, polyclonal or recombinant antibodies with high specificity and affinity for each marker protein and little cross reactivity to other proteins.
  • the ELISA kits may also comprise antibodies specific for a control protein.
  • the ELISA kits may further comprise reagents capable of detecting bound antibodies, such as labeled secondary antibodies, chromophores, enzymes (in a conjugated form with antibodies) and their substrates or other substances capable of binding to antibodies.
  • the kit of the present invention may comprise washing or eluting solutions by which substrates to be color-developed with enzymes and unbound proteins are removed, while bound protein markers are only retained.
  • the sample used for the analysis includes a biological sample capable of identifying a cancer-specific protein that can be distinguished from a healthy state, such as blood, serum, urine, tear, and saliva.
  • a biological sample capable of identifying a cancer-specific protein that can be distinguished from a healthy state, such as blood, serum, urine, tear, and saliva.
  • the analysis may be conducted by measuring from biological liquid samples, such as blood, serum, and plasma.
  • the sample may be prepared to enhance the detection sensitivity of a protein marker.
  • a serum sample obtained from a patient can be pre-treated using such methods as anion exchange chromatography, affinity chromatography, size exclusion chromatography, liquid chromatography, sequential extraction and gel electrophoresis.
  • the present invention also provides a method for diagnosing and treating a colon cancer in a subject, the method comprising the steps of:
  • the inventors first discovered that the KRS and AIMP1 can function as a novel marker of a colon cancer and provided a method for measuring the expression level of each markers to provide information necessary for the diagnosis of a colorectal or colon cancer.
  • the method of the present invention will be described in a sequential manner.
  • Step (a) of the method according to the present invention is a step of obtaining a sample from a subject.
  • the sample can be used without limitation as long as it is collected from a subject to be diagnosed as having a colorectal or colon cancer.
  • the sample may be a cell or tissue obtained by biopsy, blood, whole blood, serum, plasma, saliva, cerebrospinal fluid, various secretions, urine, feces and the like.
  • the sample may be blood, plasma, serum, saliva, nasal mucus, sputum, capsular fluid, amniotic fluid, ascites, cervical or vaginal discharge, urine or cerebrospinal fluid.
  • the sample may be blood, plasma, or serum.
  • Step (b) of the method according to the present invention is a set of measuring the expression level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) in the sample provided in step (a).
  • the expression level may be a mRNA or protein level of at least one selected from the group consisting of KRS and AIMP1.
  • the level of each protein may be detected or measured using an antibody that specifically binds to each protein.
  • the protein-specific antibody is as described above for the diagnostic composition of the present invention.
  • Methods known in the art for measuring the level of each protein can be used without limitation, and examples thereof include Western blotting, dot blotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistostaining, immunoprecipitation assay, complement fixation assay, FACS, and protein chip, but are not limited thereto.
  • an ELISA method may be used.
  • the existence and level of the mRNA of each markers in a sample of the subject can be determined by amplifying the mRNA or cDNA of each markers from a sample of the subject using a primer set or a probe that specifically binds to the mRNA of each markers or by using hybridization with a probe.
  • the primers and probes are the same as described above in the diagnostic composition of the present invention.
  • the measurement of the mRNA level can be performed by methods known in the art without any limitations.
  • RT-PCR reverse transcription polymerase chain reaction
  • competitive RT-PCR competitive RT-PCR
  • real-time RT-PCR RNase protection assay
  • northern blotting DNA microarray chip
  • RNA sequencing hybridization using nanostring
  • in situ hybridization of tissue sections but are not limited thereto.
  • Step (c) of the method of the present invention is a step of comparing the mRNA or protein level selected from the group consisting of KRS and AIMP1 of the test sample measured in step (b) with a mRNA or protein level of a normal control sample of a healthy subject, followed by step (d) diagnosing the subject with a colon cancer when the mRNA or protein level from the sample of the subject is greater than that of the normal control sample of the healthy subject; and step (e) treating the diagnosed subject by at least one of (i) administering an effective amount of a therapeutic agent for colon cancer to the diagnosed subject, (ii) conducting a curative surgery, and (iii) conducting a radiation therapy.
  • each marker of the subject measured by step (b) described above is compared with that of the healthy subject measured in the same manner. If the expression level of each markers is increased compared to a normal healthy subject, the subject is determined to have a colon cancer.
  • the present invention also provides a method for screening an anti-colon cancer agent, the method comprising the steps of:
  • mRNA or protein level of at least one selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) in the sample under the presence or absence of the anti-colon cancer agent candidate;
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • the method can be useful for screening a therapeutic agent for colon cancer by comparing the increase or decrease of a mRNA or protein level of at least one selected from the group consisting of KRS and AIMP1 under the presence and absence of an anti-colon cancer agent candidate.
  • Any candidate that indirectly or directly reduces the mRNA or protein level of at least one selected the group consisting of KRS and AIMP1 may be selected as a therapeutic agent for colon cancer. That is, the expression level of the marker of the present invention in colon cancer cells is measured under the absence of the anti-colon cancer agent candidate, while the expression level of the marker of the present invention is measured under the presence of the anti-colon cancer agent candidate, followed by the comparison of measured levels. Then, if the expression level of the marker of the present invention in the presence of the anti-colon cancer agent candidate is lower than the level in the absence of the anti-colon cancer agent candidate, said candidate may be selected as a therapeutic agent for colon cancer.
  • the ‘anticancer activity’ means an activity of inhibiting an increased abnormal cell division, transformation from normal cells into cancer cells, cell division and proliferation of cancer cells, development and growth of tumors, and the like.
  • the ‘cell or animal’ may be a cell or an animal of a cancer or tumor model. As commonly used in the art, it may be a cell, a tissue, an organ, etc. derived from an animal such as a mammal including a human.
  • the present invention provides use of an agent for measuring a mRNA or protein level of at least one selected from the group consisting of KRS (lysyl-tRNA synthetase) and AIMP1 (aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1) for preparing an agent for diagnosis of a colon cancer.
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • the agent for measuring the mRNA level may be a probe or a primer set that specifically binds to mRNA of KRS or AIMP1, as described above.
  • the agent for measuring the protein level may be an antibody specific for the KRS or AIMP1 protein, as described above.
  • the mRNA of KRS may comprise the nucleotide sequence of SEQ ID NO: 1, while the mRNA of AIMP1 may comprise the nucleotide sequence of SEQ ID NO: 2.
  • the KRS protein may comprise the amino acid sequence of SEQ ID NO: 3, while the AIMP1 protein may comprise the amino acid sequence of SEQ ID NO: 4.
  • An embodiment of the present invention provides the use of an agent for measuring a mRNA or protein level of at least one selected from the group consisting of KRS and AIMP1 for preparing a colon cancer diagnostic kit.
  • the kit of the present invention may be a RT-PCR kit, a DNA chip kit, or a protein chip kit, but is not limited thereto.
  • the colon cancer diagnostic markers of KRS and AIMP1 according to the present invention are found to have increased expression levels in the serum of colon cancer patients compared with the normal control. Therefore, by measuring the expression levels of at least one markers selected from the group consisting of KRS and AIMP1, the presence or absence of colon cancer can be accurately and rapidly verified.
  • FIGS. 1A, 1B, 1C, 1D, 1E, 1F, 1G and 1H show the serum protein levels of colon cancer patients and normal controls by dot blot, respectively (A: GRS, B: KRS, C: AIMP1, D: HRS, E: WRS, F: CA-19-9, G: TNF- ⁇ , H: IL-10).
  • FIGS. 2A, 2B and 2C are graphs showing an ROC curve of serum protein levels.
  • Serum from colon cancer patients was obtained from the Samsung Medical Center (Seoul, Republic of Korea) according to the regulations of the Clinical Examination Committee. Samples of 32 normal controls and 164 colon cancer patients were obtained and analyzed.
  • GRS glycosyl-tRNA synthetase
  • KRS lysyl-tRNA synthetase
  • HRS histidyl-tRNA synthetase
  • WRS tryptophanyl-tRNA synthetase
  • AIMP-1 aminoacyl-tRNA synthetase complex-interacting multifunctional Protein 1
  • TNF- ⁇ TNF- ⁇
  • IL-10 CA-19-9 secreted in the serum of normal controls and colon cancer patients were analyzed using an enzyme immunoassay kit according to the manufacturer's instructions, respectively.
  • the amount of protein secretion was measured using a microplate reader (TECAN).
  • the manufacturers of each serum protein assay kit are as follows:
  • TNF-a TNF-a, IL-10 (BD science, USA)
  • the P value between the proteins secreted in the serum of normal controls and colon cancer patients was analyzed using the Mann-Whitney test/Two-tailed test with XLASTAT software. Dotblot plot, ROC curve, AUC, and standard deviation were analyzed using Graphpad Prism 6 software.
  • ELISA enzyme-linked immunosorbent assay
  • KRS lysyl-tRNA synthetase
  • AIMP1 aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1
  • the AUC of KRS and AIMP1 ROC is greater than 0.6 with p value of less than 0.01, verifying that the KRS and AIMP1 are excellent colon cancer markers since the levels of KRS and AIMP1 in the serum of the colon cancer patients were statistically significantly higher than those of normal controls.
  • KRS and AIMP1 were found to be better markers than CA-19-9, a conventional biomarker of colon cancer.
  • the colon cancer diagnostic markers of KRS and AIMP1 according to the present invention are found to have increased expression levels in the serum of colon cancer patients compared with the normal control. Therefore, by measuring the expression levels of at least one markers selected from the group consisting of KRS and AIMP1, the presence or absence of colon cancer can be accurately and rapidly verified. Thus, the colon cancer diagnostic markers according to the present invention are considered to have excellent industrial applicability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US16/111,087 2016-02-25 2018-08-23 Colorectal cancer diagnostic composition, and method for detecting diagnostic marker Active 2038-03-30 US11360093B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020160022470A KR101851003B1 (ko) 2016-02-25 2016-02-25 대장암 진단용 조성물과 진단 마커 검출 방법
KRKR10-2016-0022470 2016-02-25
KR10-2016-0022470 2016-02-25
PCT/KR2017/002081 WO2017146529A1 (ko) 2016-02-25 2017-02-24 대장암 진단용 조성물과 진단 마커 검출 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/002081 Continuation-In-Part WO2017146529A1 (ko) 2016-02-25 2017-02-24 대장암 진단용 조성물과 진단 마커 검출 방법

Publications (2)

Publication Number Publication Date
US20190018015A1 US20190018015A1 (en) 2019-01-17
US11360093B2 true US11360093B2 (en) 2022-06-14

Family

ID=59685504

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/111,087 Active 2038-03-30 US11360093B2 (en) 2016-02-25 2018-08-23 Colorectal cancer diagnostic composition, and method for detecting diagnostic marker

Country Status (6)

Country Link
US (1) US11360093B2 (ja)
EP (1) EP3409790A4 (ja)
JP (1) JP6847972B2 (ja)
KR (1) KR101851003B1 (ja)
CN (1) CN109312405A (ja)
WO (1) WO2017146529A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107447033B (zh) * 2017-09-15 2020-11-17 东南大学 一种结直肠癌诊断生物标志物及其应用
KR101968046B1 (ko) * 2018-07-19 2019-04-11 (주) 바이오인프라생명과학 암의 조기 진단을 위한 복합 바이오마커
CA3117001C (en) * 2018-09-17 2023-09-19 Biocontac Co., Ltd. Antibody for specifically binding to lysyl-trna synthetase n-terminal domain exposed to extracellular membrane
CN109674797B (zh) * 2018-12-13 2021-06-01 苏州大学 一种小分子作为赖氨酰tRNA合成酶的抑制剂的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090111298A (ko) 2008-04-21 2009-10-26 한국생명공학연구원 위암 또는 대장암 진단 마커 및 치료제로서의 ｃｄｃａ５
WO2010021415A1 (en) * 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
KR20100040583A (ko) 2008-10-10 2010-04-20 서울대학교산학협력단 항-라이실 티알엔에이 합성효소 항체 및 항-라미닌 수용체 항체를 유효성분으로 포함하는 암 진단용 조성물
US8669058B2 (en) 1999-01-06 2014-03-11 Genenews, Inc. Method of profiling gene expression in a subject having colorectal cancer
WO2014185692A1 (ko) 2013-05-15 2014-11-20 재단법인 의약바이오컨버젼스연구단 3차원 콜라겐 겔 환경에서 라이실-ｔＲＮＡ 합성효소가 발현하거나 발현하지 않도록 조절된 세포 또는 회전타원체로 덩어리진 세포 배양을 이용한 암 전이 억제제의 스크리닝 방법
KR20150078472A (ko) 2013-12-30 2015-07-08 재단법인 의약바이오컨버젼스연구단 항 AIMP1/p43 모노클로날 항체 및 이의 용도
WO2015102341A1 (ko) 2013-12-30 2015-07-09 재단법인 의약바이오컨버젼스연구단 항 krs 모노클로날 항체 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000655A (es) * 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
EP2388336A1 (en) * 2010-05-19 2011-11-23 Signature Diagnostics AG Method and kits for diagnosing colorectal cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669058B2 (en) 1999-01-06 2014-03-11 Genenews, Inc. Method of profiling gene expression in a subject having colorectal cancer
KR20090111298A (ko) 2008-04-21 2009-10-26 한국생명공학연구원 위암 또는 대장암 진단 마커 및 치료제로서의 ｃｄｃａ５
WO2010021415A1 (en) * 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
KR20110046521A (ko) 2008-08-18 2011-05-04 재단법인서울대학교산학협력재단 라이실 ｔＲＮＡ 합성효소의 세포내 수준을 조절하여 암 전이 또는 암 세포의 이동을 조절하는 방법
KR20100040583A (ko) 2008-10-10 2010-04-20 서울대학교산학협력단 항-라이실 티알엔에이 합성효소 항체 및 항-라미닌 수용체 항체를 유효성분으로 포함하는 암 진단용 조성물
WO2014185692A1 (ko) 2013-05-15 2014-11-20 재단법인 의약바이오컨버젼스연구단 3차원 콜라겐 겔 환경에서 라이실-ｔＲＮＡ 합성효소가 발현하거나 발현하지 않도록 조절된 세포 또는 회전타원체로 덩어리진 세포 배양을 이용한 암 전이 억제제의 스크리닝 방법
US20160146815A1 (en) 2013-05-15 2016-05-26 Medicinal Bioconvergence Research Center Method for screeing cancer metastasis inhibitor using culture of cells or spheroidically aggregated cells in which lysyl-trna synthetase is regulated to be expressed or unexpressed
KR20150078472A (ko) 2013-12-30 2015-07-08 재단법인 의약바이오컨버젼스연구단 항 AIMP1/p43 모노클로날 항체 및 이의 용도
WO2015102341A1 (ko) 2013-12-30 2015-07-09 재단법인 의약바이오컨버젼스연구단 항 krs 모노클로날 항체 및 이의 용도
US9945859B2 (en) 2013-12-30 2018-04-17 Medicinal Bioconvergence Research Center Anti-KRS monoclonal antibody and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kim et al., "Expression of AIMP1, 2 and 3, the scaffolds for the multi-tRNA synthetase complex is downregulated in gastric and colorectal cancer", Tumori, 2011, 97: 380-385.
Lee et al. (J. Microbiol. Biotechnol., 2016, vol. 26, No. 2., pp. 432-4390; Published online Dec. 8, 2015). (Year: 2015). *
Tukalo et al., "Aminoacyl-tRNA synthetases as biomarkers for cancer diagnostics", Biopolymers and Cell, 2015, 31: 32.

Also Published As

Publication number Publication date
JP2019507594A (ja) 2019-03-22
JP6847972B2 (ja) 2021-03-24
WO2017146529A1 (ko) 2017-08-31
EP3409790A1 (en) 2018-12-05
KR20170100206A (ko) 2017-09-04
KR101851003B1 (ko) 2018-04-20
US20190018015A1 (en) 2019-01-17
CN109312405A (zh) 2019-02-05
EP3409790A4 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
US11360093B2 (en) Colorectal cancer diagnostic composition, and method for detecting diagnostic marker
KR101007567B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
US9102706B2 (en) Newly identified colon cancer marker and diagnostic kit using the same
US20230220467A1 (en) Normal-pressure hydrocephalus diagnosis composition and diagnosis marker detection method, using level of expression of chi3l1 in blood
KR102210333B1 (ko) 암의 진단용 조성물
KR20130017525A (ko) 대장암, 유방암, 신장암 또는 갑상선암의 조기 진단을 위한 바이오 마커 및 이의 용도
KR101058753B1 (ko) 대장암 마커로서의 ｅｓｍ－１ 유전자 및 이를 이용한대장암의 진단 및 치료에의 용도
KR20090053222A (ko) 체액 내 대장암 마커로서의 ｃｘｃｌ－１６유전자 및 이를이용한 대장암의 진단 및 치료에의 용도
KR101878974B1 (ko) 신장암 진단용 조성물과 진단 마커 검출 방법
KR102499664B1 (ko) 암의 진단용 조성물
KR101007573B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101007574B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR102618065B1 (ko) 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단 방법
KR100969692B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR100958086B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR102499678B1 (ko) 암의 진단용 조성물
KR102325742B1 (ko) 암의 진단용 조성물
KR20090097138A (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101060193B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101060192B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101007576B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101007575B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101065027B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
CN113817830A (zh) 用于预测结直肠癌对奥沙利铂治疗敏感性的方法
KR20130017526A (ko) 대장암, 유방암 또는 신장암의 조기 진단을 위한 바이오 마커 및 이의 용도

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: MEDICINAL BIOCONVERGENCE RESEARCH CENTER, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, SUNGHOON;PARK, MIN CHUL;GOUGHNOUR, PETER CHARLES;REEL/FRAME:047007/0825

Effective date: 20180903

Owner name: MEDICINAL BIOCONVERGENCE RESEARCH CENTER, KOREA, R

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, SUNGHOON;PARK, MIN CHUL;GOUGHNOUR, PETER CHARLES;REEL/FRAME:047007/0825

Effective date: 20180903

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE